Sunvozertinib is a targeted therapy agent indicated for the treatment of specific subtypes of non-small cell lung cancer (NSCLC). Concomitant use of the following medications should be avoided during administration:
1.Potent CYP3A4 inhibitors or inducers (e.g., ketoconazole, rifampicin), which may significantly affect the metabolism and plasma concentration of sunvozertinib;
2.Anticoagulants (e.g., warfarin), which may increase the risk of bleeding;
3.Gastric acid-regulating medications (e.g., omeprazole), which may reduce the absorption of sunvozertinib;
4.Hepatotoxic medications (e.g., acetaminophen), which may add to the hepatic burden.
Specific Medication Contraindications and Precautions
CYP3A4-Related Medications
Potent inhibitors (e.g., clarithromycin, itraconazole):May elevate the plasma concentration of sunvozertinib and increase the risk of adverse effects (e.g., diarrhea, rash).
Potent inducers (e.g., carbamazepine, phenytoin): May impair the therapeutic efficacy of sunvozertinib, necessitating dosage adjustment or medication substitution.
Recommendation: If concomitant use is unavoidable, plasma drug concentration monitoring or treatment regimen adjustment should be conducted under the guidance of a physician.
Anticoagulant and Antiplatelet Medications
Sunvozertinib may increase bleeding tendency. Close monitoring of coagulation function is required when it is used in combination with aspirin, clopidogrel and other such agents.
Gastric Acid-Regulating Medications
Proton Pump Inhibitors (PPIs) or H2 Receptor Antagonists (e.g., ranitidine): May decrease the absorption rate of sunvozertinib. It is recommended to administer the medications at an interval of more than 2 hours.
Hepatotoxic Medications
Long-term concomitant use of hepatotoxic medications may raise the risk of hepatic dysfunction. Regular monitoring of aminotransferase and other relevant liver function markers is necessary.
Other Medications Requiring Cautious Concomitant Use
Immunosuppressants (e.g., cyclosporine) and QT-prolonging agents (e.g., amiodarone) may increase the risk of adverse reactions when used with sunvozertinib.
Medication Guidelines
Administer as prescribed
Sunvozertinib is a prescription drug. The prescribed dosage and treatment course must be strictly followed; no self-adjustment or unprescribed concomitant use of other medications is allowed.
Regular monitoring
During treatment, regular examinations of liver function, coagulation function and electrocardiogram (ECG) are required, especially when sunvozertinib is used in combination with high-risk medications.
Seek immediate medical attention
Discontinue the medication and consult a doctor immediately if abnormal bleeding, jaundice, severe diarrhea or cardiac arrhythmia occurs.
If concomitant use of any other medications (including Chinese herbal medicines and health supplements) is needed, inform your physician or pharmacist in advance for a comprehensive assessment of the potential risk of drug-drug interactions.
